Search for "Negishi" in Full Text gives 69 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2013, 9, 2762–2766, doi:10.3762/bjoc.9.310
Graphical Abstract
Figure 1: Structures of resolvins D1 (1) and D2 (2).
Scheme 1: Retrosynthetic analysis of RvD2 (1).
Scheme 2: Synthesis of aldehyde 7 and phosphonium salt 6.
Scheme 3: Synthesis of vinyl iodide 4.
Scheme 4: Synthesis of enyne 3.
Scheme 5: Completion of the synthesis of RvD2 (1).
Beilstein J. Org. Chem. 2013, 9, 2641–2659, doi:10.3762/bjoc.9.300
Graphical Abstract
Figure 1: Structures of limonene, carvone and thalidomide.
Figure 2: Structure of Garner’s aldehyde.
Scheme 1: (a) i) Boc2O, 1.0 N NaOH (pH >10), dioxane, +5 °C → rt; ii) MeI, K2CO3, DMF, 0 °C → rt (86% over tw...
Scheme 2: (a) AcCl, MeOH, 0 °C → reflux (99%); (b) i) (Boc)2O, Et3N, THF, 0 °C → rt → 50 °C (89%); ii) Me2C(O...
Scheme 3: (a) LiAlH4, THF, rt (93–96%); (b) (COCl)2, DMSO, iPr2NEt, CH2Cl2, −78 °C → −55 °C (99%).
Scheme 4: The Koskinen procedure for the preparation of Garner’s aldehyde. (a) i) AcCl, MeOH, 0 °C → 50 °C (9...
Scheme 5: Burke’s synthesis of Garner’s aldehyde. BDP - bis(diazaphospholane).
Figure 3: Structures of some iminosugars (7, 9), peptide antibiotics (8) and sphingosine (10) and pachastriss...
Scheme 6: Use of Garner’s aldehyde 1 in multistep synthesis.
Scheme 7: Explanation of the anti- and syn-selectivity in the nucleophilic addition reaction.
Scheme 8: Herold’s method: (a) Lithium 1-pentadecyne, HMPT, THF, −78 °C (71%); (b) Lithium 1-pentadecyne, ZnBr...
Scheme 9: (a) Ethyl lithiumpropiolate, HMPT, THF, −78 °C; (b) (S)- or (R)-MTPA, DCC, DMAP, THF, rt (18, 81%) ...
Scheme 10: Coleman’s selectivity studies and their transition state model for the co-ordinated delivery of the...
Scheme 11: (a) PhMgBr, THF, −78 °C → 0 °C [62] or (a) PhMgBr, Et2O, 0 °C [63].
Scheme 12: (a) cat. RhCl3·3H2O, cat. 26, NaOMe, Ph-B(OH)2, aq DME, 80 °C (24, 71%); (b) cat. RhCl3·3H2O, cat. ...
Scheme 13: Lithiated dithiane (3 equiv), CuI (0.3 equiv), BF3·Et2O (6 equiv), THF, −50 °C, 12 h (70%).
Scheme 14: Addition reaction reported by Lam et al. (a) 1-Hexyne, n-BuLi, THF, −15 °C or −40 °C.
Scheme 15: (a) n-BuLi, HMPT, toluene, −78 °C → rt (85%); (b) n-BuLi, ZnCl2, toluene/Et2O, −78 °C → rt (65%).
Scheme 16: (a) n-BuLi, 34, THF, −40 °C [69]; (b) n-BuLi, 35, THF, −78 °C → rt (80%) [70]; (c) n-BuLi, 35, HMPT, THF, −...
Scheme 17: (a) cat. Rh(acac)(CO)2, 42, THF, 40 °C (74%).
Scheme 18: (a) 1-PropynylMgBr, CuI, THF, Me2S, −78 °C (95%); (b) Ethynyltrimethylsilane, EtMgBr, CuI, THF, Me2...
Scheme 19: (a) cat. 50, toluene, 0 °C (52%); (b) cat. 51, toluene, 0 °C (51%); (c) cat. 52, toluene, 0 °C (50%...
Scheme 20: (a) (iPr)3SiH, cat. Ni(COD)2, dimesityleneimidazolium·HCl, t-BuOK, THF, rt.
Scheme 21: (a) Cp2Zr(H)Cl, cat. AgAsF6, CH2Cl2, rt; (b) Cp2Zr(H)Cl, 1-pentadecyne, cat. ZnBr2 in THF for anti-...
Scheme 22: (a) i) 31, n-BuLi, THF, −78 °C; ii) (S)-1, THF, −78 °C; (b) Red-Al, THF, 0 °C.
Scheme 23: (a) 61, n-BuLi, DMPU, toluene, −78 °C, then (S)-1, toluene, −95 °C (57%); (b) 61, n-BuLi, ZnCl2, to...
Scheme 24: Olefin A as an intermediate in natural product synthesis.
Scheme 25: (a) Ph3(Me)PBr, KH, benzene (66%, rac-64) or (b) AlMe3, Zn, CH2I2, THF (76%) [101]; (c) Ph3(Me)PBr, n-Bu...
Scheme 26: (a) Benzene, rt (82%) [108]; (b) K2CO3, MeOH (85%) [89]; (c) iPrOH, [Ir(COD)Cl]2, PPh3, THF, rt (81%) [114].
Scheme 27: Mechanism of the Still–Gennari modification of the HWE reaction leading to both olefin isomers.
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 278–302, doi:10.3762/bjoc.9.34
Graphical Abstract
Scheme 1: Variation of substrates for carbomagnesiation and carbozincation in this article.
Scheme 2: Copper-catalyzed arylmagnesiation and allylmagnesiation of alkynyl sulfone.
Scheme 3: Copper-catalyzed four-component reaction of alkynyl sulfoxide with alkylzinc reagent, diiodomethane...
Scheme 4: Rhodium-catalyzed reaction of aryl alkynyl ketones with arylzinc reagents.
Scheme 5: Allylmagnesiation of propargyl alcohol, which provides the anti-addition product.
Scheme 6: Negishi’s total synthesis of (Z)-γ-bisabolene by allylmagnesiation.
Scheme 7: Iron-catalyzed syn-carbomagnesiation of propargylic or homopropargylic alcohol.
Scheme 8: Mechanism of iron-catalyzed carbomagnesiation.
Scheme 9: Regio- and stereoselective manganese-catalyzed allylmagnesiation.
Scheme 10: Vinylation and alkylation of arylacetylene-bearing hydroxy group.
Scheme 11: Arylmagnesiation of (2-pyridyl)silyl-substituted alkynes.
Scheme 12: Synthesis of tamoxifen from 2g.
Scheme 13: Controlling regioselectivity of carbocupration by attaching directing groups.
Scheme 14: Rhodium-catalyzed carbozincation of ynamides.
Scheme 15: Synthesis of 4-pentenenitriles through carbometalation followed by aza-Claisen rearrangement.
Scheme 16: Uncatalyzed carbomagnesiation of cyclopropenes.
Scheme 17: Iron-catalyzed carbometalation of cyclopropenes.
Scheme 18: Enantioselective carbozincation of cyclopropenes.
Scheme 19: Copper-catalyzed facially selective carbomagnesiation.
Scheme 20: Arylmagnesiation of cyclopropenes.
Scheme 21: Enantioselective methylmagnesiation of cyclopropenes without catalyst.
Scheme 22: Copper-catalyzed carbozincation.
Scheme 23: Enantioselective ethylzincation of cyclopropenes.
Scheme 24: Nickel-catalyzed ring-opening aryl- and alkenylmagnesiation of a methylenecyclopropane.
Scheme 25: Reaction mechanism.
Scheme 26: Nickel-catalyzed carbomagnesiation of arylacetylene and dialkylacetylene.
Scheme 27: Nickel-catalyzed carbozincation of arylacetylenes and its application to the synthesis of tamoxifen....
Scheme 28: Bristol-Myers Squibb’s nickel-catalyzed phenylzincation.
Scheme 29: Iron/NHC-catalyzed arylmagnesiation of aryl(alkyl)acetylene.
Scheme 30: Iron/copper-cocatalyzed alkylmagnesiation of aryl(alkyl)acetylenes.
Scheme 31: Iron-catalyzed hydrometalation.
Scheme 32: Iron/copper-cocatalyzed arylmagnesiation of dialkylacetylenes.
Scheme 33: Chromium-catalyzed arylmagnesiation of alkynes.
Scheme 34: Cobalt-catalyzed arylzincation of alkynes.
Scheme 35: Cobalt-catalyzed formation of arylzinc reagents and subsequent arylzincation of alkynes.
Scheme 36: Cobalt-catalyzed benzylzincation of dialkylacetylene and aryl(alkyl)acetylenes.
Scheme 37: Synthesis of estrogen receptor antagonist.
Scheme 38: Cobalt-catalyzed allylzincation of aryl-substituted alkynes.
Scheme 39: Silver-catalyzed alkylmagnesiation of terminal alkyne.
Scheme 40: Proposed mechanism of silver-catalyzed alkylmagnesiation.
Scheme 41: Zirconium-catalyzed ethylzincation of terminal alkenes.
Scheme 42: Zirconium-catalyzed alkylmagnesiation.
Scheme 43: Titanium-catalyzed carbomagnesiation.
Scheme 44: Three-component coupling reaction.
Scheme 45: Iron-catalyzed arylzincation reaction of oxabicyclic alkenes.
Scheme 46: Reaction of allenyl ketones with organomagnesium reagent.
Scheme 47: Regio- and stereoselective reaction of a 2,3-allenoate.
Scheme 48: Three-component coupling reaction of 1,2-allenoate, organozinc reagent, and ketone.
Scheme 49: Proposed mechanism for a rhodium-catalyzed arylzincation of allenes.
Scheme 50: Synthesis of skipped polyenes by iterative arylzincation/allenylation reaction.
Scheme 51: Synthesis of 1,4-diorganomagnesium compound from 1,2-dienes.
Scheme 52: Synthesis of tricyclic compounds.
Scheme 53: Manganese-catalyzed allylmagnesiation of allenes.
Scheme 54: Copper-catalyzed alkylmagnesiation of 1,3-dienes and 1,3-enynes.
Scheme 55: Chromium-catalyzed methallylmagnesiation of 1,6-diynes.
Scheme 56: Chromium-catalyzed allylmagnesiation of 1,6-enynes.
Scheme 57: Proposed mechanism of the chromium-catalyzed methallylmagnesiation.
Beilstein J. Org. Chem. 2012, 8, 2214–2222, doi:10.3762/bjoc.8.250
Graphical Abstract
Scheme 1: Strategy for the synthesis of (1,4-dihydro)pyridines by deprotonation/intramolecular carbolithiatio...
Scheme 2: Feasibility of the deprotonation/intramolecular carbolithiation.
Scheme 3: Synthesis of the starting N-allyl-ynamides.
Scheme 4: Intramolecular carbolithiation of N-allyl-ynamides to 1,4-dihydropyridines and pyridines.
Scheme 5: 2,3-Disubstituted pyridines by trapping of the intermediate metallated 1,4-dihydropyridine.
Scheme 6: Formal synthesis of the anti-dyskinesia agent, 5-HT1A receptor agonist, dopamine D2 receptor ligand...
Beilstein J. Org. Chem. 2012, 8, 2202–2206, doi:10.3762/bjoc.8.248
Graphical Abstract
Scheme 1: Synthesis of tetrasubstituted olefins by a successive carbocupration and S–Li exchange.
Scheme 2: Proposed mechanism of the sulfur–lithium exchange starting with the alkenyl thioether 4.
Scheme 3: Synthesis of the precursor 1a.
Scheme 4: Carbocupration of the thioether 1a leading to the tetrasubstituted alkene 4a.
Scheme 5: Synthesis of the alkenyllithium reagent 7a by an S–Li exchange.
Scheme 6: Quenching of the alkynyllithium 7a. (Product ratios and diastereoselectivities were determined by 1...
Scheme 7: Synthesis and quenching of Z-styryllithium.
Beilstein J. Org. Chem. 2012, 8, 1936–1998, doi:10.3762/bjoc.8.225
Graphical Abstract
Figure 1: Loschmidt’s structure proposal for benzene (1) (Scheme 181 from [3]) and the corresponding modern stru...
Figure 2: The first isolated bisallenes.
Figure 3: Carbon skeletons of selected bisallenes discussed in this review.
Scheme 1: The preparation of 1,2,4,5-hexatetraene (2).
Scheme 2: The preparation of a conjugated bisallene by the DMS-protocol.
Scheme 3: Preparation of the 3-deuterio- and 3,4-dideuterio derivatives of 24.
Scheme 4: A versatile method to prepare alkylated conjugated bisallenes and other allenes.
Scheme 5: A preparation of 3,4-dimethyl-1,2,4,5-hexatetraene (38).
Scheme 6: A (C6 + 0)-approach to 1,2,4,5-hexatetraene (2).
Scheme 7: The preparation of a fully alkylated bisallenes from a 2,4-hexadiyne-1,6-diol diacetate.
Scheme 8: The preparation of the first phenyl-substituted conjugated bisallenes 3 and 4.
Scheme 9: Selective hydrogenation of [5]cumulenes to conjugated bisallenes: another (C6 + 0)-route.
Scheme 10: Aryl-substituted conjugated bisallenes by a (C3 + C3)-approach.
Scheme 11: Hexaphenyl-1,2,4,5-hexatetraene (59) by a (C3 + C3)-approach.
Scheme 12: An allenation route to conjugated bisallenes.
Scheme 13: The preparation of 3,4-difunctionalized conjugated bisallenes.
Scheme 14: Problems during the preparation of sulfur-substituted conjugated bisallenes.
Scheme 15: The preparation of 3,4-dibromo bisallenes.
Scheme 16: Generation of allenolates by an oxy-Cope rearrangement.
Scheme 17: A linear trimerization of alkynes to conjugated bisallenes: a (C2 + C2 + C2)-protocol.
Scheme 18: Preparation of a TMS-substituted conjugated bisallene by a C3-dimerization route.
Scheme 19: A bis(trimethylsilyl)bisallene by a C3-coupling protocol.
Scheme 20: The rearrangement of highly substituted benzene derivatives into their conjugated bisallenic isomer...
Scheme 21: From fully substituted benzene derivatives to fully substituted bisallenes.
Scheme 22: From a bicyclopropenyl to a conjugated bisallene derivative.
Scheme 23: The conversion of a bismethylenecyclobutene into a conjugated bisallene.
Scheme 24: The preparation of monofunctionalized bisallenes.
Scheme 25: Preparation of bisallene diols and their cyclization to dihydrofurans.
Scheme 26: A 3,4-difunctionalized conjugated bisallene by a C3-coupling process.
Scheme 27: Preparation of a bisallenic diketone by a coupling reaction.
Scheme 28: Sulfur and selenium-substituted bisallenes by a [2.3]sigmatropic rearrangement.
Scheme 29: The biallenylation of azetidinones.
Scheme 30: The preparation of a fully ferrocenylated conjugated bisallene.
Scheme 31: The first isomerization of a 1,5-hexadiyne to a 1,2,4,5-hexatetraene.
Scheme 32: The preparation of alkynyl-substituted bisallenes by a C3-dimerization protocol.
Scheme 33: Preparation of another completely ferrocenylated bisallene.
Scheme 34: The cyclization of 1,5-hexadiyne (129) to 3,4-bismethylenecyclobutene (130) via 1,2,4,5-hexatetraen...
Scheme 35: Stereochemistry of the thermal cyclization of bisallenes to bismethylenecyclobutenes.
Scheme 36: Bisallene→bismethylenecyclobutene ring closures in the solid state.
Scheme 37: A bisallene cyclization/dimerization reaction.
Scheme 38: A selection of Diels–Alder additions of 1,2,4,5-hexatetraene with various double-bond dienophiles.
Scheme 39: The stereochemistry of the [2 + 4] cycloaddition to conjugated bisallenes.
Scheme 40: Preparation of azetidinone derivatives from conjugated bisallenes.
Scheme 41: Cycloaddition of heterodienophiles to a conjugated bisallene.
Scheme 42: Addition of triple-bond dienophiles to conjugated bisallenes.
Scheme 43: Sulfur dioxide addition to conjugated bisallenes.
Scheme 44: The addition of a germylene to a conjugated bisallene.
Scheme 45: Trapping of conjugated bisallenes with phosphinidenes.
Scheme 46: The cyclopropanantion of 1,2,4,5-hexatetraene (2).
Scheme 47: Photochemical reactions involving conjugated bisallenes.
Scheme 48: Base-catalyzed isomerizations of conjugated bisallenes.
Scheme 49: Ionic additions to a conjugated bisallene.
Scheme 50: Oxidation reactions of a conjugated bisallene.
Scheme 51: The mechanism of oxidation of the bisallene 24.
Scheme 52: CuCl-catalyzed cyclization of 1,2,4,5-hexatetraene (2).
Scheme 53: The conversion of conjugated bisallenes into cyclopentenones.
Scheme 54: Oligomerization of a conjugated bisallene by nickel catalysts.
Scheme 55: Generation of 1,2,5,6-heptatetraene (229) as a reaction intermediate.
Scheme 56: The preparation of a stable derivative of 1,2,5,6-heptatetraene.
Scheme 57: A bisallene with a carbonyl group as a spacer element.
Scheme 58: The first preparation of 1,2,6,7-octatetraene (242).
Scheme 59: Preparation of 1,2,6,7-octatetraenes by (C4 + C4)-coupling of enynes.
Scheme 60: Preparation of 1,2,6,7-octatetraenes by (C4 + C4)-coupling of homoallenyl bromides.
Scheme 61: Preparation of 1,2,6,7-octatetraenes by alkylation of propargylic substrates.
Scheme 62: Preparation of two highly functionalized 1,2,6,7-octatetraenes.
Scheme 63: Preparation of several higher α,ω-bisallenes.
Scheme 64: Preparation of different alkyl derivatives of α,ω-bisallenes.
Scheme 65: The preparation of functionalized 1,2,7,8-nonatetraene derivatives.
Scheme 66: Preparation of functionalized α,ω-bisallenes.
Scheme 67: The preparation of an α,ω-bisallene by direct homologation of an α,ω-bisalkyne.
Scheme 68: The gas-phase pyrolysis of 4,4-dimethyl-1,2,5,6-heptatetraene (237).
Scheme 69: Gas-phase pyrolysis of 1,2,6,7-octatetraene (242).
Scheme 70: The cyclopropanation of 1,2,6,7-octatetraene (242).
Scheme 71: Intramolecular cyclization of 1,2,6,7-octatetraene derivatives.
Scheme 72: The gas-phase pyrolysis of 1,2,7,8-nonatetraene (265) and 1,2,8,9-decatetraene (266).
Scheme 73: Rh-catalyzed cyclization of a functionalized 1,2,7,8-nonatetraene.
Scheme 74: A triple cyclization involving two different allenic substrates.
Scheme 75: Bicyclization of keto derivatives of 1,2,7,8-nonatetraene.
Scheme 76: The preparation of complex organic compounds from functionalized bisallenes.
Scheme 77: Cycloisomerization of an α,ω-bisallene containing a C9 tether.
Scheme 78: Organoborane polymers from α,ω-bisallenes.
Scheme 79: Preparation of trans- (337) and cis-1,2,4,6,7-octapentaene (341).
Scheme 80: The preparation of 4-methylene-1,2,5,6-heptatetraene (349).
Scheme 81: The preparation of acetylenic bisallenes.
Scheme 82: The preparation of derivatives of hydrocarbon 351.
Scheme 83: The construction of macrocyclic alleno-acetylenes.
Scheme 84: Preparation and reactions of 4,5-bismethylene-1,2,6,7-octatetraene (365).
Scheme 85: Preparation of 1,2-bis(propadienyl)benzene (370).
Scheme 86: The preparation of 1,4-bis(propadienyl)benzene (376).
Scheme 87: The preparation of aromatic and heteroaromatic bisallenes by metal-mediated coupling reactions.
Scheme 88: Double cyclization of an aromatic bisallene.
Scheme 89: Preparation of an allenic [15]paracyclophane by a ring-closing metathesis reaction of an aromatic α...
Scheme 90: Preparation of a macrocyclic ring system containing 1,4-bis(propadienyl)benzene units.
Scheme 91: Preparation of copolymers from 1,4-bis(propadienyl)benzene (376).
Scheme 92: A boration/copolymerization sequence of an aromatic bisallene and an aromatic bisacetylene.
Scheme 93: Formation of a layered aromatic bisallene.
Figure 4: The first members of the semicyclic bisallene series.
Scheme 94: Preparation of the first bis(vinylidene)cyclobutane derivative.
Scheme 95: Dimerization of strain-activated cumulenes to bis(vinylidene)cyclobutanes.
Scheme 96: Photodimerization of two fully substituted butatrienes in the solid state.
Scheme 97: Preparation of the two parent bis(vinylidene)cyclobutanes.
Scheme 98: The preparation of 1,3-bis(vinylidene)cyclopentane and its thermal isomerization.
Scheme 99: The preparation of the isomeric bis(vinylidene)cyclohexanes.
Scheme 100: Bi- and tricyclic conjugated bisallenes.
Scheme 101: A selection of polycyclic bisallenes.
Scheme 102: The first endocyclic bisallenes.
Figure 5: The stereochemistry of 1,2,6,7-cyclodecatetraene.
Scheme 103: The preparation of several endocyclic bisallenes.
Scheme 104: Synthesis of diastereomeric derivatives of 1,2,6,7-cyclodecatetraene.
Scheme 105: Preparation of a derivative of 1,2,8,9-cyclotetradecatetraene.
Scheme 106: The preparation of keto derivatives of cyclic bisallenes.
Scheme 107: The preparation of cyclic biscumulenic ring systems.
Scheme 108: Cyclic bisallenes in natural- and non-natural-product chemistry.
Scheme 109: The preparation of iron carbonyl complexes from cyclic bisallenes.
Figure 6: A selection of unknown exocyclic bisallenes that should have interesting chemical properties.
Scheme 110: The thermal isomerization of 1,2-diethynylcyclopropanes and -cyclobutanes.
Scheme 111: Intermediate generation of a cyclooctapentaene.
Scheme 112: Attempted preparation of a cyclodecahexaene.
Scheme 113: The thermal isomerization of 1,5,9-cyclododecatriyne (511) into [6]radialene (514).
Scheme 114: An isomerization involving a diketone derived from a conjugated bisallene.
Scheme 115: Typical reaction modes of heteroorganic bisallenes.
Scheme 116: Generation and thermal behavior of acyclic hetero-organic bisallenes.
Scheme 117: Generation of bis(propadienyl)thioether.
Scheme 118: The preparation of a bisallenic sulfone and its thermal isomerization.
Scheme 119: Bromination of the bisallenic sulfone 535.
Scheme 120: Metalation/hydrolysis of the bisallenic sulfone 535.
Scheme 121: Aromatic compounds from hetero bisallenes.
Scheme 122: Isomerization/cyclization of bispropargylic ethers.
Scheme 123: The preparation of novel aromatic systems by base-catalyzed isomerization of bispropargyl ethers.
Scheme 124: The isomerization of bisacetylenic thioethers to bicyclic thiophenes.
Scheme 125: Aromatization of macrocyclic bispropargylic sulfides.
Scheme 126: Preparation of ansa-compounds from macrocyclic bispropargyl thioethers.
Scheme 127: Alternate route for cyclization of a heterorganic bisallene.
Scheme 128: Multiple isomerization/cyclization of “double” bispropargylic thioethers.
Scheme 129: Preparation of a bisallenyl disulfide and its subsequent bicyclization.
Scheme 130: Thermal cyclization of a bisallenyl thiosulfonate.
Scheme 131: Some reactions of heteroorganic bisallenes with two sulfur atoms.
Scheme 132: Further methods for the preparation of heteroorganic bisallenes.
Scheme 133: Cyclization reactions of heteroorganic bisallenes.
Scheme 134: Thermal cycloadditions of bisallenic tertiary amines.
Scheme 135: Cyclization of a bisallenic tertiary amine in the presence of a transition-metal catalyst.
Scheme 136: A Pauson–Khand reaction of a bisallenic ether.
Scheme 137: Formation of a 2:1adduct from two allenic substrates.
Scheme 138: A ring-forming silastannylation of a bisallenic tertiary amine.
Scheme 139: A three-component cyclization involving a heterorganic bisallene.
Scheme 140: Atom-economic construction of a complex organic framework from a heterorganic α,ω-bisallene.
Beilstein J. Org. Chem. 2012, 8, 675–682, doi:10.3762/bjoc.8.75
Graphical Abstract
Scheme 1: Different strategies to access C-glycosides starting from 1-substituted glycals.
Scheme 2: Sonogashira–Hagihara reaction of 1-iodo-2-chloroglucal 12 with phenylacetylene (8a) to afford 13.
Beilstein J. Org. Chem. 2012, 8, 379–389, doi:10.3762/bjoc.8.41
Graphical Abstract
Figure 1: Structure and atomic numbering of 2,2’:6’,2’’-terpyridines.
Scheme 1: Synthesis of furanyl-substituted terpyridines 12–14 by using Kröhnke’s method.
Scheme 2: Synthesis of terpyridines under solvent-free conditions.
Scheme 3: Preparation of 4,4′,4′′-trisubstituted terpyridine containing carboxylate moieties.
Scheme 4: Synthetic pathway for the preparation of a furanyl-functionalised quinquepyridine.
Scheme 5: Utilization of an iminium salt in the preparation of a furanyl-substituted tpy.
Figure 2: Chemical structure of U- and S-shaped isomers.
Scheme 6: Preparation of an asymmetric furanyl-substituted terpyridine.
Scheme 7: Synthesis of tpy by Stille cross-coupling reaction.
Scheme 8: Oxidation of the furan ring of furanyl-substituted terpyridines.
Scheme 9: Direct oxidation of a furan ring attached on Ru(II) tpy complexes.
Figure 3: Example of polyoxometalate frameworks functionalised with tpy ligands and tpy-complex (reprinted wi...
Scheme 10: Synthetic pathway to europium(III) and samarium(III) chelates 56 and 57.
Scheme 11: Synthetic pathway to prepare thiocyanato-functionalised tpys as potential biomolecule-labelling age...
Scheme 12: Synthetic sequence envisioned for biomolecules labelling by click-chemistry.
Figure 4: Structure of pyrrolyl (66), thienyl (67) and bithienyl (68)-substituted complexes analogous to comp...
Beilstein J. Org. Chem. 2011, 7, 1722–1731, doi:10.3762/bjoc.7.202
Graphical Abstract
Figure 1: Dimethylaminophenylene end-capped sexithiophenes 1a and 1b, and dialkyl end-capped sexithiophenes 2a...
Scheme 1: The synthesis of functionalised oligothiophenes 1a,b and 2a,b. Reagents and conditions: a) NBS, CH3...
Figure 2: Solid-state voltammograms of 1b and 2b, as spin-coated films on ITO glass, versus Ag/AgCl reference...
Figure 3: Absorption spectra in solution (dichloromethane) and solid state.
Figure 4: UV–visible spectroelectrochemical measurements of 1b (left) and 2b (right) drop-cast onto ITO glass....
Figure 5: Absorption spectra for 1b and 2b, together with the absorption and emission profiles for the CdSe(Z...
Figure 6: The absorption spectra of increasing sexithiophene concentration with HDA capped CdSe(ZnS) quantum ...
Figure 7: Photoluminescence quenching experiments; the effect of increasing sexithiophene concentration with ...
Beilstein J. Org. Chem. 2011, 7, 1584–1601, doi:10.3762/bjoc.7.187
Graphical Abstract
Scheme 1: Stoichiometric and catalytic direct (hetero)arylation of arenes.
Scheme 2: Stille and Negishi cross-coupling methodologies in oxazole series [28,30,31,33,34].
Scheme 3: Stoichiometric direct (hetero)arylation of (benz)oxazole with magnesate bases [35].
Scheme 4: Ohta's pioneering catalytic direct C5-selective pyrazinylation of oxazole [36,37].
Scheme 5: Preparation of pharmaceutical compounds by following the pioneering Ohta protocol [38,39].
Scheme 6: Miura’s pioneering catalytic direct arylations of (benz)oxazoles [40]. aIsolated yield.
Scheme 7: Pd(0)- and Cu(I)-catalyzed direct C2-selective arylation of (benz)oxazoles [41-44].
Scheme 8: Cu(I)-catalyzed direct C2-selective arylations of (benz)oxazoles [40,45-47].
Scheme 9: Copper-free Pd(0)-catalyzed direct C5- and C2-selective arylation of oxazole-4-carboxylate esters [48-50,52].
Scheme 10: Iterative synthesis of bis- and trioxazoles [51].
Scheme 11: Preparation of DPO- and POPOP-analogues [53].
Scheme 12: Pd(0)-catalyzed direct arylation of benzoxazole with aryl chlorides [54].
Scheme 13: Pd(0)-catalyzed direct C2-selective arylation of (benz)oxazoles with bromides and chlorides using b...
Scheme 14: Palladium-catalyzed direct arylation of oxazoles under green conditions; (a) Zhuralev direct arylat...
Scheme 15: Pd(0)-catalyzed C2- and C5-selective (hetero)arylation of oxazole [63].
Scheme 16: Pd(0)-catalyzed C2- and C5-selective (hetero)arylation of ethyl oxazole-4-carboxylate [64].
Scheme 17: Pd(0)-catalyzed direct C4-phenylation of oxazoles; (a) Miura’s procedure [65]; (b) Fagnou’s procedure [66].
Scheme 18: Catalytic cycles for Cu(I)-catalyzed (routeA) and Pd(0)/Cu(I)-catalyzed (route B) direct arylation ...
Scheme 19: Base-assisted, Pd(0)-catalyzed, C2-selective, direct arylation of benzoxazole proposed by Zhuralev [58]...
Scheme 20: Electrophilic substitution-type mechanism proposed by Hoarau [64].
Scheme 21: CMD-proceeding C5-selective direct arylation of oxazole proposed by Strotman and Chobabian [63].
Scheme 22: DFT calculations on methyl oxazole-4-carboxylate and consequently developed methodologies for the P...
Scheme 23: Pd(0)-catalyzed direct arylation of (benz)oxazoles with tosylates and mesylates [71].
Scheme 24: Pd(0)-catalyzed direct arylation of oxazoles with sulfamates [72].
Scheme 25: Pd(II)- and Cu(II)-catalyzed decarboxylative direct C–H coupling of oxazoles with 4- and 5-carboxyo...
Scheme 26: Pd(II)- and Ag(II)-catalyzed decarboxylative direct arylation of (benzo)oxazoles [74]; (a) procedure; (...
Scheme 27: Pd(II)- and Cu(II)-catalyzed direct arylation of benzoxazole with arylboronic acids [76]; (a) procedure...
Scheme 28: Ni(II)-catalyzed direct arylation of benzoxazoles with arylboronic acids under O2 [76]; (a) procedure; ...
Scheme 29: Rhodium-catalyzed direct arylation of benzoxazole [78,79].
Scheme 30: Ni(II)-catalyzed direct arylation of (benz)oxazoles with aryl halides; (a) Itami's procedure [80]; (b) ...
Scheme 31: Dehydrogenative cross-coupling of (benz)oxazoles; (a) Pd(II)- and Cu(II)-catalyzed cross-coupling o...
Beilstein J. Org. Chem. 2011, 7, 1261–1277, doi:10.3762/bjoc.7.147
Graphical Abstract
Scheme 1: Preparation of polyfunctional heteroarylzinc reagents.
Scheme 2: LiCl-mediated insertion of zinc dust to aryl and heteroaryl iodides.
Scheme 3: Selective insertions of Zn in the presence of LiCl.
Scheme 4: Chemoselective insertion of zinc in the presence of LiCl.
Scheme 5: Preparation and reactions of benzylic zinc reagents.
Scheme 6: Ni-catalyzed cross-coupling of benzylic zinc reagent 34 with ethyl 2-chloronicotinate.
Scheme 7: In situ generation of arylzinc reagents using Mg in the presence of LiCl and ZnCl2.
Scheme 8: Zincation of heterocycles with TMP2Zn (42).
Scheme 9: Preparation of highly functionalized zincated heterocycles using TMP2Zn·2MgCl2·2LiCl (42).
Scheme 10: Microwave-accelerated zincation of heterocycles using TMP2Zn·2MgCl2·2LiCl (42).
Scheme 11: The I/Mg-exchange as a metal-metathesis reaction.
Scheme 12: Regioselective Br/Mg-exchange of dibromoquinolines 65 and 68.
Scheme 13: Improved reagents for the regioselective Br/Mg-exchange on bromoquinolines.
Scheme 14: Synthesis of ellipticine (83) using an I/Mg-exchange reaction.
Scheme 15: An oxidative amination leading to the biologically active adenine, purvalanol A (84).
Scheme 16: Preparation of polyfunctional arylmagnesium reagents using Mg in the presence of LiCl.
Scheme 17: Preparation of polyfunctional magnesium reagents starting from organic chlorides.
Scheme 18: Selective multiple magnesiation of the pyrimidine ring.
Scheme 19: Synthesis of a p38 kinase inhibitor 119 and of a sPLA2 inhibitor 123.
Scheme 20: Synthesis of highly substituted indoles of type 128.
Scheme 21: Efficient magnesiations of polyfunctional aromatics and heterocycles using TMP2Mg·2LiCl (129).
Scheme 22: Negishi cross-coupling in the presence of substrates bearing an NH- or an OH-group.
Scheme 23: Negishi cross-coupling in the presence of a serine moiety.
Scheme 24: Radical catalysis for the performance of very fast Kumada reactions.
Scheme 25: MgCl2-mediated addition of functionalized aromatic, heteroaromatic, alkyl and benzylic organozincs ...
Beilstein J. Org. Chem. 2011, 7, 1215–1218, doi:10.3762/bjoc.7.141
Figure 1: Directed aromatic functionalization methods.
Beilstein J. Org. Chem. 2011, 7, 824–830, doi:10.3762/bjoc.7.94
Graphical Abstract
Scheme 1: One-pot hydrozirconation-reductive coupling of allene 2 and nitrile 7.
Scheme 2: Cyclization of allenylnitrile 18.
Figure 1: Coupling constant analysis of the Boc-protected aminopyran ring in 21.
Scheme 3: Proposed chelated transition state model.
Scheme 4: Conversion of homoallylic amines to β-amino acid derivatives.
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Beilstein J. Org. Chem. 2011, 7, 386–393, doi:10.3762/bjoc.7.49
Graphical Abstract
Figure 1: Methods for synthesis of dibromides I and their use for preparation of 6-membered heterocycles.
Scheme 1: General methods for preparation of diols VII.
Scheme 2: General methods for preparation of tetrahydropyrans VIII.
Figure 2: Structures of 1,5-dibromomopentanes 1a–1d.
Scheme 3: Preparation of dibromides 1.
Scheme 4: Preparation of diol 2a.
Scheme 5: Preparation of diol 2b.
Scheme 6: Preparation of tetrahydropyrans 3a–3c.
Scheme 7: Preparation of tetrahydropyran 3d.
Scheme 8: Preparation of methylenetetrahydropyrans 6.
Scheme 9: Preparation of bromides 8 and 10.
Scheme 10: Preparation of sulfonium derivatives 11.
Beilstein J. Org. Chem. 2010, 6, No. 27, doi:10.3762/bjoc.6.27
Graphical Abstract
Figure 1: Valsartan.
Scheme 1: Retrosynthetic analysis of 8.
Scheme 2: (a) Et3N, CH2Cl2, 0 °C, 95%; (b) NaH, THF, 70%; (c) n-BuLi, 25 °C, THF, anhyd ZnCl2, −20 °C, Q-phos...
Beilstein J. Org. Chem. 2009, 5, No. 33, doi:10.3762/bjoc.5.33
Graphical Abstract
Scheme 1: Aziridine containing natural products.
Scheme 2: Mitomycin structures and nomenclature.
Scheme 3: Base catalysed epimerization of mitomycin B.
Scheme 4: Biosynthesis of mitomycin C (MMC) 7.
Scheme 5: Mode of action of mitomycin C.
Scheme 6: The N–C3–C9a disconnection.
Scheme 7: Danishefsky’s Retrosynthesis of mitomycin K.
Scheme 8: Hetero Diels–Alder reaction en route to mitomycins.
Scheme 9: Nitroso Diels–Alder cycloaddition.
Scheme 10: Frank azide cycloadddition.
Scheme 11: Final steps of mitomycin K synthesis. aPDC, DCM; bPhSCH2N3, PhH, 80 °C; cL-selectride, THF, −78 °C; ...
Scheme 12: Naruta–Maruyama retrosynthesis.
Scheme 13: Synthesis of a leucoaziridinomitosane by nitrene cycloaddition. aAlCl3-Et2O; bNaH, ClCH2OMe; cn-BuL...
Scheme 14: Thermal decomposition of azidoquinone 51.
Scheme 15: Diastereoselectivity during the cycloaddition.
Scheme 16: Oxidation with iodo-azide.
Scheme 17: Williams’ approach towards mitomycins.aDEIPSCl, Imidazole, DCM; bPd/C, HCO2NH4, MeOH; cAllocCl, NaH...
Scheme 18: Synthesis of pyrrolidones by homoconjugate addition.
Scheme 19: Homoconjugate addition on the fully functionalized substrate.
Scheme 20: Introduction of the olefin.
Scheme 21: Retrosynthesis of N–C9a, N–C3 bond formation.
Scheme 22: Synthesis of the pyrrolo[1,2]indole 82 using N-PSP activation.aAc2O, Py; bAc2O, Hg(OAc)2, AcOH, 90%...
Scheme 23: Synthesis of an aziridinomitosane. am-CPBA, DCM then iPr2NH, CCl4 reflux; bK2CO3, MeOH; cBnBr, KH; d...
Scheme 24: Oxidation products of a leucoaziridinomitosane obtained from a Polonovski oxidation.
Scheme 25: Polonovski oxidation of an aziridinomitosane. am-CPBA; bPd/C, H2; cDimethoxypropane, PPTS.
Scheme 26: The C1–C9a disconnection.
Scheme 27: Ziegler synthesis of desmethoxymitomycin A.aIm2C=O, THF; bNH3; cTMSOTf, 2,6-di-tert-butylpyridine, ...
Scheme 28: Transformation of sodium erythorbate.aTBDMSCl; bNaN3; cPPh3; d(Boc)2O, DMAP; eTBAF; fTf2O, Pyr.
Scheme 29: Formation of C9,C10-unsaturation in the mitomycins. am-CPBA, DCM; bO3, MeOH; cMe2S; dKHMDS, (EtO)3P...
Scheme 30: Fragmentation mechanism.
Scheme 31: Michael addition-cyclisation.
Scheme 32: SmI2 8-endo-dig cyclisation.
Scheme 33: Synthesis of pyrrolo[1,2-a]indole by 5-exo-dig radical cyclization.
Scheme 34: The C9–C9a disconnection.
Scheme 35: Intramolecular nitrile oxide cycloaddition.
Scheme 36: Regioselectivity of the INOC.
Scheme 37: Fukuyama’s INOC strategy.
Scheme 38: Synthesis of a mitosane core by rearrangement of a 1-(1-pyrrolidinyl)-1,3-butadiene.
Scheme 39: Sulikowski synthesis of an aziridinomitosene. aPd(Tol3P)2Cl2, Bu3SnF, 140; bH2, Pd/C; cTFAA, Et3N; d...
Scheme 40: Enantioselective carbene insertion.
Scheme 41: Parson’s radical cyclization.
Scheme 42: Cha’s mitomycin B core synthesis.
Scheme 43: The N-aromatic disconnection.
Scheme 44: Kishi retrosynthesis.
Scheme 45: Kishi synthesis of a starting material. aallyl bromide, K2CO3, acetone, reflux; bN,N-Dimethylanilin...
Scheme 46: Kishi synthesis of MMC 7. aLDA, THF, −78 °C then PhSeBr, THF, −78 °C; bH2O2, THF-EtOAc; cDIBAL, DCM...
Scheme 47: Acid catalyzed degradation of MMC 7.
Scheme 48: In vivo formation of apomitomycin B.
Scheme 49: Advanced intermediate for apomitomycin B synthesis.
Scheme 50: Remers synthesis of a functionalized mitosene. aTMSCl, Et3N, ZnCl2 then NBS; bAcOK; cNH2OH; dPd/C, H...
Scheme 51: Coleman synthesis of desmethoxymitomycin A. aSnCl2, PhSH, Et3N, CH3CN; bClCO2Bn, Et3N; cPPh3, DIAD,...
Scheme 52: Transition state and pyrrolidine synthesis.
Scheme 53: Air oxidation of mitosanes and aziridinomitosanes.
Scheme 54: The C9-aromatic disconnection.
Scheme 55: Synthesis of the aziridine precursor. aLHMDS, THF; bNaOH; c(s)-α-Me-BnNH2, DCC, HOBT; dDIBAL; eK2CO3...
Scheme 56: Synthesis of 206 via enamine conjugate addition.
Scheme 57: Rapoport synthesis of an aziridinomitosene.
Scheme 58: One pot synthesis of a mitomycin analog.
Scheme 59: Synthesis of compound 218 via intramolecular Heck coupling. aEtMgCl, THF, then 220; bMsCl, Et3N; cN...
Scheme 60: Elaboration of indole 223. aEt3N, Ac2O; bAcOH; cSOCl2, Et3N; dNaN3, DMF; eH2SO4, THF; fK2CO3, MeOH; ...
Scheme 61: C9-C9a functionalization from indole.
Scheme 62: Synthesis of mitomycin K. a2 equiv. MoO5.HMPA, MeOH; bPPh3, Et3N, THF-H2O; cMeOTf, Py, DCM; dMe3SiCH...
Scheme 63: Configurational stability of mitomycin K derivatives.
Scheme 64: Epimerization of carbon C9a in compound 227b.
Scheme 65: Corey–Chaykovsky synthesis of indol 235.
Scheme 66: Cory intramolecular aza-Darzens reaction for the formation of aziridinomitosene 239.
Scheme 67: Jimenez synthesis of aziridinomitosene 242.
Scheme 68: Von Braun opening of indoline 244.
Scheme 69: C9a oxidation of an aziridinomitosane with DDQ/OsO4.
Scheme 70: Synthesis of epi-mitomycin K. aNaH, Me2SO4; bH2, Pd/C; cMitscher reagent [165]; d[(trimethylsilyl)methyl...
Scheme 71: Mitomycins rearrangement.
Scheme 72: Fukuyama’s retrosynthesis.
Scheme 73: [2+3] Cycloaddition en route to isomitomycin A. aToluene, 110 °C; bDIBAL, THF, −78 °C; cAc2O, Py.; d...
Scheme 74: Final steps of Fukuyama’s synthesis.
Scheme 75: “Crisscross annulation”.
Scheme 76: Synthesis of 274; the 8-membered ring 274 was made using a crisscross annulation. a20% Pd(OH)2/C, H2...
Scheme 77: Conformational analysis of compound 273 and 275.
Scheme 78: Synthesis of a mitomycin analog. aNa2S2O4, H2O, DCM; bBnBr (10 equiv), K2CO3, 18-crown-6 (cat.), TH...
Scheme 79: Vedejs retrosynthesis.
Scheme 80: Formation of the azomethine ylide.
Scheme 81: Vedejs second synthesis of an aziridinomitosene. aDIBAL; bTPAP, NMO; c287; dTBSCl, imidazole.
Scheme 82: Trityl deprotection and new aziridine protecting group 300.
Scheme 83: Ene reaction towards benzazocinones.
Scheme 84: Benzazocenols via homo-Brook rearrangement.
Scheme 85: Pt-catalyzed [3+2] cycloaddition.
Scheme 86: Carbonylative lactamization entry to benzazocenols. aZn(OTf)2, (+)-N-methylephedrine, Et3N, TMS-ace...
Scheme 87: 8 membered ring formation by RCM. aBOC2O, NaHCO3; bTBSCl, Imidazole, DMF; callyl bromide, NaH, DMF; ...
Scheme 88: Aziridinomitosene synthesis. aTMSN3; bTFA; cPOCl3, DMF; dNaClO2, NaH2PO4, 2-methyl-2-butene; eMeI, ...
Scheme 89: Metathesis from an indole.
Scheme 90: Synthesis of early biosynthetic intermediates of mitomycins.
Beilstein J. Org. Chem. 2008, 4, No. 36, doi:10.3762/bjoc.4.36
Graphical Abstract
Figure 1: Calix[4]arene in cone conformation.
Scheme 1: Preparation of 3a and 3b.
Scheme 2: Preparation of 4 and 5.
Scheme 3: Preparation of 6.
Scheme 4: Preparation of 8 and 9.
Figure 2: Full (top), top (bottom left)a, and side (bottom right)a views of 5; afluorous chains omitted for c...